Skip to content

Atossa’s COVID-19 nasal spray receives second positive safety review

September 17, 2020

Atossa Therapeutics (ATOS +14.7%) has announced a positive interim safety assessment from the second cohort of 8 healthy participants in Phase 1 study of AT-301 administered by nasal spray, for the treatment of COVID-19.

Enrollment in the next cohort to follow, which will be the third of a total of four cohorts and the first of two multi-dose, placebo controlled cohorts.

The ongoing Phase 1 study in 32 participants has a primary objective to evaluate the safety and tolerability of AT-301. Secondary objectives are to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation. The study is being conducted inĀ Australia.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: